RBL Bank has significantly underperformed the benchmark Nifty bank index over the last 5 years. The stock has lost 67 percent of its value over the last 5 years. Read More RBL Bank has significantly underperformed the benchmark Nifty bank… और पढ़ें »RBL Bank jumps 6% after analyst meet
The growth in revenue for EID Parry will be driven by an expansion in the distillery segment. Read More The growth in revenue for EID Parry will be driven by an expansion in the distillery segment. The growth in revenue… और पढ़ें »EID Parry rises 4%, sees revenue touching Rs 1,200 crore by FY25
From its 52-week low of Rs 374, the stock has doubled to Rs 780-level over the past three months Read More From its 52-week low of Rs 374, the stock has doubled to Rs 780-level over the past three months… और पढ़ें »Olectra Greentech hits fresh 52-week high, 2x returns in 3 months
A vacation bench of justices Sudhanshu Dhulia and K V Vishwanathan took note of the submissions for urgent hearing of lawyer Ashwini Updhyay, and said it will not be taking up such pleas during the summer vacation. Read More A… और पढ़ें »SC refuses urgent listing of plea challenging RBI decision on Rs 2,000 banknote exchange
The firm reported a 52-percent increase in consolidated net profit at Rs 294 crore for the March quarter, aided by robust sales. Revenue rose to Rs 2,053 crore from Rs 1,726 crore in the year-ago period. Read More The firm… और पढ़ें »Antique cuts Mankind#39;s target price, maintains buy rating on the stock
For the fiscal year 2024, Welspun Corp aims to achieve a topline of Rs 15,000 crore, representing a strong growth of around 50 percent. Furthermore, its target for EBIDTA stands at Rs 1,500 crore, growth of around 90 percent. It… और पढ़ें »Welspun Corp up 9% in 2 days as D-Street cheers FY24 guidance
KR Choksey is bullish on Supriya Lifesciences has recommended buy rating on the stock with a target price of Rs 292 in its research report dated May 31, 2023. Read More KR Choksey is bullish on Supriya Lifesciences has recommended… और पढ़ें »Buy Supriya Lifesciences; target of Rs 292: KR Choksey
Brokerage firm CLSA expects Bharti Airtel#39;s shares to cross Rs 1,000 over the next 12 months. Read More Brokerage firm CLSA expects Bharti Airtel#39;s shares to cross Rs 1,000 over the next 12 months. Brokerage firm CLSA expects Bharti Airtel#39;s… और पढ़ें »Bharti Airtel tops Sensex losers’ chart with 3.5% drop
KR Choksey is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 1172 in its research report dated May 31, 2023. Read More KR Choksey is bullish on Sun Pharmaceutical Industries… और पढ़ें »Buy Sun Pharmaceutical Industries; target of Rs 1172: KR Choksey
Many first-time employees baulk at investing their first salary because they feel it is too low. All it takes is Rs 500 to start a SIP in a mutual fund. Read More Many first-time employees baulk at investing their first… और पढ़ें »Your first salary should be where your investment journey begins
हिन्दी 
English